ReviewFrontiers in cellular and infection microbiology2020
Utilizing Organoid and Air-Liquid Interface Models as a Screening Method in the Development of New Host Defense Peptides.
Review in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Pooled it
- Virulence arresting drug discovery by strategies targeting bacterial virulence: Mainly focusing on quorum-sensing interference and biofilm inhibition.Journal of pharmaceutical analysis · 2025Review
- Organotypic Airway Models Derived from Primary Human Nasal Epithelial Cells.Current allergy and asthma reports · 2025Review
- Lung organoids in COPD: recent advances and future prospects.Respiratory research · 2025Review
- Advances in engineered organoid models of skin for biomedical research.Burns & trauma · 2025Review
- Precision-cut lung slices in air-liquid interface (PCLS-ALI): A novelbioRxiv : the preprint server for biology · 2024Article
- Peptide-mimetic treatment of Pseudomonas aeruginosa in a mouse model of respiratory infection.Communications biology · 2024Article
- Revealing the pathogenesis of gastric intestinal metaplasia based on the mucosoid air-liquid interface.Journal of translational medicine · 2024Article
- Three-Dimensional Tumor Models to Study Cancer Stemness-Mediated Drug Resistance.Cellular and molecular bioengineering · 2024Review
- On the path to predicting immune responses in the lung: Modeling the pulmonary innate immune system at the air-liquid interface (ALI).European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2023Review
- Article
- Alternatives to animal models to study bacterial infections.Folia microbiologica · 2023Review
- Role of three-dimensional cell culture in therapeutics and diagnostics: an updated review.Drug delivery and translational research · 2023Review
- Cell Cultures at the Air-Liquid Interface and Their Application in Cancer Research.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Lung organoids: current strategies for generation and transplantation.Cell and tissue research · 2022Review
- Lung Organoids in Smoking Research: Current Advances and Future Promises.Biomolecules · 2022Review
- Mucus-targeting therapies of defective mucus clearance for cystic fibrosis: A short review.Current opinion in pharmacology · 2022Review
- Efficacy of Cathelicidin-Mimetic Antimicrobial Peptoids against Staphylococcus aureus.Microbiology spectrum · 2022Article
- Aerosol-Cell Exposure System Applied to Semi-Adherent Cells for Aerosolization of Lung Surfactant and Nanoparticles Followed by High Quality RNA Extraction.Nanomaterials (Basel, Switzerland) · 2022Article
- The role of physical cues in the development of stem cell-derived organoids.European biophysics journal : EBJ · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Host defense peptides (HDPs), also known as antimicrobial peptides, are naturally occurring polypeptides (~12-50 residues) composed of cationic and hydrophobic amino acids that adopt an amphipathic conformation upon folding usually after contact with membranes. HDPs have a variety of biological activities including immunomodulatory, anti-inflammatory, anti-bacterial, and anti-biofilm functions. Although HDPs have the potential to address the global threat of antibiotic resistance and to treat immune and inflammatory disorders, they have yet to achieve this promise. Indeed, there are several challenges associated with bringing peptide-based drug candidates from the lab bench to clinical practice, including identifying appropriate indications, stability, toxicity, and cost. These challenges can be addressed in part by the development of innate defense regulator (IDR) peptides and peptidomimetics, which are synthetic derivatives of HDPs with similar or better efficacy, increased stability, and reduced toxicity and cost of the original HDP. However, one of the largest gaps between basic research and clinical application is the validity and translatability of conventional model systems, such as cell lines and animal models, for screening HDPs and their derivatives as potential drug therapies. Indeed, such translation has often relied on animal models, which have only limited validity. Here we discuss the recent development of human organoids for disease modeling and drug screening, assisted by the use of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.